ArticleKidney medicine2025
Pretransplant Serum Creatinine in Peritoneal Dialysis Patients Predicts Graft Outcomes.
Article in Kidney medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Rationale & Objective: Although peritoneal dialysis (PD) as a pretransplant dialysis modality is associated with favorable outcomes after kidney transplant, it is unknown if pretransplant serum creatinine (Scr) level is associated with subsequent graft outcomes in candidates managed with PD. Our objective was to examine the association between Scr at the time of transplant and short-term and long-term outcomes posttransplant. Study Design: Retrospective cohort study. Setting & Participants: A total of 20,166 adult (≥18 years of age) patients who were receiving PD at the time of a first living or deceased donor kidney transplant in the United States between 2000 and 2017, identified using the Scientific Registry of Transplant Recipients database. Exposures: Primary exposure was final Scr level before transplant, categorized as <5, 5-8, 8-12, and >12 mg/dL. Sensitivity analyses for patient subgroups included recipient age (≥50 vs <50 years) and dialysis vintage (≥3 vs <3 years) at transplant. Outcomes: The primary outcome was death-censored graft loss (DCGL). Secondary outcomes included all-cause graft loss and delayed graft function (DGF). Results: Pretransplant Scr was significantly associated with DCGL (adjusted HR, 1.17; 95% CI, 1.02-1.34 for Scr >12 mg/dL [reference <5 mg/dL]) and DGF (adjusted OR, 2.71; 95% CI, 2.26-3.26 for Scr >12 mg/dL [reference <5 mg/dL]). There was no association with all-cause graft loss. The risk of DCGL and DGF associated with high pretransplant Scr was higher for those who were older (≥50 years) and those with longer dialysis vintage (≥3 years). Limitations: No access to potential predictors of pretransplant Scr including residual kidney function, dialysis adequacy and adherence; exact timing of Scr values pretransplant was unknown. Conclusions: To our knowledge, this is the first study to explore the association between pretransplant Scr level in PD patients and graft outcomes after kidney transplantation. The reason for this increased risk is unclear but may reflect reduced residual kidney function, among other factors.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.